Gonadotrophin Releasing Hormone

Phase 3Biologic

Gonadotrophin Releasing Hormone is one of 81 biologic programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaCompleted

Prostate CancerActive, not recruiting

Prostate AdenocarcinomaPreclinical

Completed

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Gonadotrophin Releasing Hormone

MMedical Research Council

Phase 3

2 2

Novantrone

Pfizer

Preclinical

5 3

Trexall

Alnylam Pharmaceuticals

Duragesic

1 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Statin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer

Unknown status·SSt. Bartholomew's Hospital·Phase 3·NCT00363285·900 enrolled

Radiation Therapy in Treating Patients With Prostate Cancer

Completed·MMedical Research Council·Phase 3·NCT00003290·800 enrolled

Prostate Adenocarcinoma1 trial

Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)

Completed·NNRG Oncology·Preclinical·NCT04037254·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Gonadotrophin Releasing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gonadotrophin Releasing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gonadotrophin Releasing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical Research Council company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: MMedical Research Council

Gonadotrophin Releasing Hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer2 trials

Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News